GBM, for example (quote: “Glioblastoma (GBM) is a highly aggressive, fast-growing cancer of the brain’s supporting tissue (grade IV astrocytoma). It is the most common adult brain tumor, occurring frequently in those aged 45–70. There is no cure for the disease, but surgery, radiation therapy, and chemotherapy are used as treatments to alleviate symptoms and slow growth.”) is a likely beneficiary. So yes, the market opportunities for BEX are immense.
14 Likes